At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,842 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Prospective, Observational, Non-Interventional Cohort Study Evaluating On-Treatment Predictors of Response in Subjects With HBeAg Positive and HBeAg Negative Chronic Hepatitis B Receiving Therapy With PEGASYS(R) (Peginterferon Alfa-2a 40KD)
In Brief
An observational study for Hepatitis B, Chronic. Completed, enrolled 1,842 participants across 249 sites in 27 countries.
Detailed Summary
This observational, non-interventional cohort study will evaluate predictors of response in patients with chronic hepatitis B receiving standard of care Pegasys therapy. Efficacy and safety parameters will also be evaluated. Patients included in the study will be followed for the duration of their treatment and for up to 3 years thereafter.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B, Chronic
CountriesAustria, Bahrain, Bangladesh, Bosnia and Herzegovina, Bulgaria, China, Egypt, France, Germany, Hong Kong, India, Indonesia, Ireland, Jordan, Lebanon, Morocco, New Zealand, North Macedonia, Pakistan, Poland, Portugal, Romania, Saudi Arabia, South Korea, Thailand, United Arab Emirates, United Kingdom
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2009
First PostedNov 2009
Primary CompletionNov 2014
TodayJul 2026
First PostedNov 11, 2009
Enrollment StartApr 11, 2009
Primary CompletionNov 18, 2014
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 16.6 years ago